Psoriasis
Explore original articles, case reports, and podcasts that focus on psoriasis.
Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study
August 2017 | Volume 16 | Issue 8 | Original Article | 801 | Copyright © August 2017
INTRODUCTION: Many options are available for patients with moderate to severe plaque psoriasis. Patients with moderate disease, however, are often undertreated and do not achieve satisfactory clear...
Read MoreTreatment of Inverse/Intertriginous Psoriasis: Updated Guidelines from the Medical Board of the National Psoriasis Foundation
August 2017 | Volume 16 | Issue 8 | Original Article | 760 | Copyright © August 2017
Inverse or intertriginous psoriasis commonly involves skin fold areas including the axillae, perianal skin, intergluteal cleft, inframammary, genital/inguinal, abdominal, and retroauricular folds. ...
Read MoreA Major Win for the Treatment of Nail Psoriasis
August 2017 | Volume 16 | Issue 8 | Editorials | 731 | Copyright © August 2017
Despite mounting evidence that biologics provide the fastest and most efficacious for nail psoriasis, it remains challenging for patients to get access to these medications, often requiring concomitan...
Read MoreInjection Site Reactions to Biologic Agents Used in Psoriasis and Psoriatic Arthritis
July 2017 | Volume 16 | Issue 7 | Case Reports | 695 | Copyright © July 2017
Psoriasis is a chronic inflammatory cutaneous disease that affects 2-3% of the general population. Up to 30% of patients with psoriasis also develop psoriatic arthritis, a chronic inflammatory and ...
Read MoreTwo Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque Psoriasis
March 2017 | Volume 16 | Issue 3 | Original Article | 234 | Copyright © March 2017
BACKGROUND: A novel lotion formulation of halobetasol propionate, 0.05% (HBP Lotion) with enhanced vehicle characteristics of a cream while preserving the ease of use and cosmetic elegance of a lot...
Read MoreA Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis
March 2017 | Volume 16 | Issue 3 | Original Article | 197 | Copyright © March 2017
BACKGROUND: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Treatment options focus on r...
Read MoreRheological Properties of Calcium Hydroxylapatite With Integral Lidocaine
September 2016 | Volume 15 | Issue 9 | Original Article | 1107 | Copyright © September 2016
BACKGROUND: Calcium hydroxylapatite with integral lidocaine, CaHA (+), received FDA approval in 2015 and CE mark approval in 2016. This formulation has been associated with significant pain reduction ...
Read MoreIxekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3
August 2016 | Volume 15 | Issue 8 | Original Article | 958 | Copyright © August 2016
BACKGROUND: Ixekizumab, a monoclonal antibody that selectively targets interleukin-17A, has been established as safe and effective in 3 Phase 3 trials for the treatment of moderate to severe plaque ps...
Read MoreEfficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris: a Randomized Phase III Study (PSO-FAST)
December 2015 | Volume 14 | Issue 12 | Original Article | 1468 | Copyright © December 2015
INTRODUCTION: An innovative aerosol foam formulation of calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) designed to improve treatment outcomes.
OBJECTIVE: To compare the ef...
Read MoreSafety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
July 2015 | Volume 14 | Issue 7 | Original Article | 706 | Copyright © July 2015
BACKGROUND: Safety surveillance is needed for biologic therapies for psoriasis.
OBJECTIVE: To assess the risk of adverse events of special interest (AEoSIs) with ustekinumab and other psoriasis t...
Read MoreClinical Study Results of Desoximetasone Spray, 0.25% in Moderate to Severe Plaque Psoriasis
December 2013 | Volume 12 | Issue 12 | Original Article | 1404 | Copyright © December 2013
Two Phase 3, double-blind, randomized, vehicle-controlled parallel studies evaluated the efficacy and safety of desoximetasone spray 0.25%, a super-potent topical corticosteroid, twice daily vs vehicl...
Read MoreA Case of Bupropion-induced Stevens-Johnson Syndrome With Acute Psoriatic Exacerbation
August 2010 | Volume 9 | Issue 8 | Case Reports | 1010 | Copyright © August 2010
Bupropion is a very popular medication prescribed to millions of patients globally for depression (Wellbutrin®, GlaxoSmithKline, Research Triangle Park, NC) as well as an aid in smoking cessation ...
Read MoreThe Management of Psoriasis in the Age of Biologics: Clinical Update 2009
September 2009 | Volume 8 | Issue 9 | Department | 5 | Copyright © September 2009
This activity is supported by an educational donation provided by Astellas Pharma US Inc. and Amg...
Read More